Clinical trials: Head and Neck Cancers
Esophageal Cancer
AI-Driven Digital Twin and Drug Simulation for Esophageal Cancer
This study aims to integrate multi-omics data (genomics, transcriptomics, proteomics) from esophageal cancer patients with artificial intelligence and digital twin technology to construct personalized virtual patient models that…
- Trial name
- ESCA-DT (NCT07757022)
- Testing
- Toripalimab, Paclitaxel, Cisplatin
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Radiation Treatment, Neurovascular Complications
Long-term Neurovascular Complications After Radiation Therapy in Head and Neck Cancer
Head and neck cancer is a group of cancers develop from the soft tissues, salivary gland, mucosa of the upper respiratory or digestive system covering the oral and nasal cavity.
- Trial name
- NCT06111430
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Biomarkers in Patients With Head and Neck Cancer
RATIONALE: DNA analysis of tumor tissue may help doctors predict how well patients will respond to treatment. PURPOSE: This research study is studying biomarkers in patients with head and neck cancer.
- Trial name
- NCT01466257
- Testing
- cetuximab, cisplatin, DNA analysis
- Volunteers
- 70 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Esophageal Squamous Cell Carcinoma
The Prognostic Value of Tertiary Lymphatic Structure in Esophageal Squamous Cell Carcinoma
Retrospective analysis of the presence and maturity of tertiary lymphoid structures in pathological sections of patients with esophageal squamous cell carcinoma after surgical treatment.
- Trial name
- NCT06241066
- Testing
- no-Intervention
- Where
- China
- Volunteers
- 359 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Thyroid Cancer, Papillary Microcarcinoma
Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others
The purpose of this study is to understand more about why some patients choose to have surgery to treat their papillary microcarcinoma (PMC) and others choose to have their papillary microcarcinoma (PMC) regularly watched by…
- Trial name
- NCT01392222
- Testing
- Focus groups
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Carcinoma of the Head and Neck
Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN
The purpose of this study was to identify which cancer-related genes are turned on or turned off in order to determine how well a patient will respond to the study drug, panitumumab.
- Trial name
- TOP0901 (NCT01305772)
- Testing
- Panitumumab, Surgery, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neal Ready
Thyroid Neoplasms, Carcinoma
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this.
- Conditions
- Thyroid Neoplasms, Carcinoma, Thyroid Cancer, Metastatic Cancer
- Trial name
- NCT00804830
- Testing
- Bevacizumab
- Where
- 3 sites in Sweden
- Volunteers
- 15 people
- Sponsor
- Region Skane
Head and Neck Cancers
Evaluation Clinique Des Performances Du Dispositif D'Aide À La Chirurgie Dyameo
During the surgical removal of head and neck tumours, the correct determination of the boundary between healthy and tumour tissue is critical.
- Trial name
- ETCETERA (NCT06618170)
- Testing
- Tissue surface analysis with the device
- Volunteers
- 80 people
- Sponsor
- Dyameo
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
This phase II trial studies how well cemiplimab works before surgery in treating patients with stage II-IV head and neck cutaneous squamous cell cancer that has come back (recurrent) and can be removed by surgery (resectable).
- Conditions
- Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
- Trial name
- NCT03565783
- Testing
- Cemiplimab
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Esophageal Cancer, Sentinel Lymph Node
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy
Sentinel lymph nodes, as the primary site of tumor metastasis, play a pivotal role in assessing patient prognosis and planning subsequent treatment strategies.
- Conditions
- Esophageal Cancer, Sentinel Lymph Node, Lymphadenectomy, Indocyanine Green
- Trial name
- NCT07303231
- Testing
- Minimally invasive surgery for esophageal cancer using near-infrared indocyanine green fluorescence to visualize the sentinel lymph node
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Neoplasm, Immunotherapy
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
This is an exploratory phase II clinical study designed to evaluate the safety and efficacy of Camrelizumab in combination with standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable esophageal…
- Conditions
- Esophageal Neoplasm, Immunotherapy, Radiotherapy
- Trial name
- NCT05176002
- Testing
- Camrelizumab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Medical University Union Hospital
Esophageal Cancer, Active Surveillance
Statistical Analysis Plan for the SANO-trial: Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Active Surveillance for Oesophageal Cancer
An active surveillance approach is proposed after completion of neoadjuvant chemoradiotherapy (nCRT) for carcinoma of the oesophagus. In this SANO (i.e.
- Conditions
- Esophageal Cancer, Active Surveillance, Neoadjuvant Chemoradiotherapy, Surgical Oncology
- Trial name
- SANO (NCT05953181)
- Testing
- Active surveillance
- Where
- Netherlands
- Volunteers
- 776 people
- Sponsor
- Erasmus Medical Center
Head and Neck Cancer, HPV
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
The purpose of this study is to assess the objective response rate following neoadjuvant therapy with volrustomig, paclitaxel, and carboplatin in previously untreated human papillomavirus (HPV)-negative locally advanced head and…
- Trial name
- NCT07065630
- Testing
- Volrustomig, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Chicago
Head and Neck Neoplasms
Effects of Nutritional Counseling on Nutritional Status and Quality of Life of Head and Neck Cancer Patients
This study investigates the effects of nutritional counseling versus standard nutritional care on nutritional status and quality of life in patients with head and neck cancer submitted to radiotherapy.Half participants will…
- Trial name
- NCT03114202
- Testing
- intensive nutritional counseling, Standard care
- Where
- 2 sites in Brazil
- Volunteers
- 90 people
- Sponsor
- University of Sao Paulo General Hospital
Hnscc, Head and Neck
Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
The goal of this Phase 1 clinical trial is to evaluate the safety and feasibility of nivolumab-IRDye800CW (nivo800) as a molecular imaging agent in adults with biopsy-confirmed or presumed head and neck squamous cell carcinoma…
- Conditions
- Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma
- Trial name
- NCT07460765
- Testing
- Nivo800, Nivolumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06469944
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine
- Where
- 50 sites in United States, Brazil and 10 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Thyroid Cancer
Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics in Patients Prepared With Recombinant Human TSH Injection (rhTSH)
This research study is to compare the radiopharmacokinetics of I-124 to the radiopharmacokinetics of I-131 in patients who have well-differentiated thyroid cancer after recombinant human thyroid-stimulating hormone (rhTSH)…
- Trial name
- NCT00926978
- Testing
- Radioactive Iodine 124
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Medstar Health Research Institute
Head and Neck Cancer
A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment
The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have…
- Trial name
- NCT07179315
- Testing
- cemiplimab+fianlimab, Cemiplimab
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- University of Chicago
Nasopharyngeal Carcinoma
SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.
This is an open label, single-arm, multi-center, phase 2 Study of SHR-1210 in recurrent/metastatic nasopharyngeal carcinoma(R/M NPC) patients who have received previous at least two lines of chemotherapy.
- Trial name
- NCT03558191
- Testing
- SHR-1210
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Brain Injuries
Effect of Bevacizumab on Asymptomatic Radiotherapy-induced Brain Injury
To investigate the effect of Bevacizumab on asymptomatic radiotherapy-induced brain injury patients with head and neck cancer.
- Trial name
- BRAIN (NCT05303259)
- Testing
- Bevacizumab
- Where
- China
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.